

Special Issue

Vaccines against Bacterial Respiratory Infections

Message from the Guest Editors

While accruing data is showing a reduction in the incidence of bacterial respiratory infections during the pandemic owing to public health measures introduced to tackle COVID-19, these diseases remain a huge threat, and a resurgence can be expected as the pandemic subsides. Research into the development of vaccines—which have proven to be indispensable in the fight against these infections—must continue, but now with the significant incorporation of new strategies and technologies, some of which were instrumental in the rapid development of the COVID-19 vaccines. This Special Issue of *Vaccines* will highlight specific groundbreaking research covering all stages of the bacterial vaccine development process, from antigen discovery through assessments of immune responses in experimental human challenge models to the monitoring of impact and non-specific events. In this Issue, focus will also be preferentially given to those bacterial pathogens that cause human disease.

Guest Editors

Prof. Dr. Paul Langford

Dr. Vanessa S. Terra

Dr. Fadil Bidmos

Dr. Alice Halliday

Deadline for manuscript submissions

closed (31 October 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/99691

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).